-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical News, April 1st, Zhang Huawei resigned, Long Jing has been appointed
Chairman's resignation has taken effect
On March 30, Weigao Co.
, Ltd.
issued an announcement on "The appointment and resignation of directors, and the re-election of retiring independent non-executive directors and the chairman of the board of directors, chief executive officer and authorized representative changes for more than nine years.
, Ltd.
issued an announcement on "The appointment and resignation of directors, and the re-election of retiring independent non-executive directors and the chairman of the board of directors, chief executive officer and authorized representative changes for more than nine years.
The above announcement shows that Zhang Huawei has resigned as executive director, chairman of the board of directors and authorized representative of Weigao Co.
, Ltd.
, effective from March 30, 2021.
, Ltd.
, effective from March 30, 2021.
Wang Yi has resigned as an executive director of Weigao Co.
, Ltd.
, effective March 30, 2021.
, Ltd.
, effective March 30, 2021.
Long Jing has resigned as the chief executive officer of Weigao Co.
, Ltd.
, effective March 30, 2021.
Long Jing has been appointed as the chairman and authorized representative of Weigao, effective March 30, 2021.
, Ltd.
, effective March 30, 2021.
Long Jing has been appointed as the chairman and authorized representative of Weigao, effective March 30, 2021.
Cong Rinan has been appointed as the chief executive officer of Weigao Co.
, Ltd.
, effective from March 30, 2021.
He has been nominated as an executive director of Weigao shares, subject to shareholder approval, etc.
, Ltd.
, effective from March 30, 2021.
He has been nominated as an executive director of Weigao shares, subject to shareholder approval, etc.
According to the above announcement, Zhang Huawei has resigned as executive director, chairman of the board of directors and authorized representative of Ben Weigao Co.
, Ltd.
due to work arrangements.
He has confirmed that he has no disagreement with the board of directors, and there is no matter related to his resignation that needs to be brought to the Stock Exchange and shareholders.
Note.
, Ltd.
due to work arrangements.
He has confirmed that he has no disagreement with the board of directors, and there is no matter related to his resignation that needs to be brought to the Stock Exchange and shareholders.
Note.
Long Jing has resigned as the chief executive officer and has been appointed as the chairman and authorized representative of Weigao Co.
, Ltd.
, effective March 30, 2021.
In view of Weigao's leading position in the Chinese market, as well as the potential to expand into the global market with its extensive product portfolio and new products under development, this move aims to allow Longjing to focus on the Group's strategic planning and development.
Mr.
Long will continue to oversee business operations and the new CEO will report directly to him.
, Ltd.
, effective March 30, 2021.
In view of Weigao's leading position in the Chinese market, as well as the potential to expand into the global market with its extensive product portfolio and new products under development, this move aims to allow Longjing to focus on the Group's strategic planning and development.
Mr.
Long will continue to oversee business operations and the new CEO will report directly to him.
Annual results announcement
According to information on the official website of Weigao shares, Zhang Huawei is 56 years old and has served as the chairman and executive director of Weigao shares and chairman of Weigao Group Co.
, Ltd.
, Ltd.
Zhang Huawei studied politics and economics at Shandong University at Weihai from 1996 to 1998.
Zhang Huawei served as the deputy factory director of Weigao Group from 1988 to 1998 and the general manager of Weigao Group since 1998.
Zhang Huawei joined Weigao in December 2000.
Zhang Huawei served as the deputy factory director of Weigao Group from 1988 to 1998 and the general manager of Weigao Group since 1998.
Zhang Huawei joined Weigao in December 2000.
Long Jing is 45 years old and used to be the chief executive officer and executive director of Weigao Co.
, Ltd.
, responsible for the company's marketing management.
Longjing has more than ten years of valuable experience in sales and marketing in the Chinese medical device industry.
, Ltd.
, responsible for the company's marketing management.
Longjing has more than ten years of valuable experience in sales and marketing in the Chinese medical device industry.
Longjing joined Weigao Co.
, Ltd.
in July 2005 and served as the deputy manager and sales manager of the company's sales management department.
Before joining Weigao, Longjing served as a sales executive in Shandong Plastics Industry Corporation from 1996 to 2002, mainly responsible for the sales and marketing of raw materials.
, Ltd.
in July 2005 and served as the deputy manager and sales manager of the company's sales management department.
Before joining Weigao, Longjing served as a sales executive in Shandong Plastics Industry Corporation from 1996 to 2002, mainly responsible for the sales and marketing of raw materials.
On March 30, Weigao Co.
, Ltd.
announced its 2020 results.
In 2020, Weigao Co.
, Ltd.
and its subsidiaries recorded revenue of approximately RMB 11,345,252,000 (approximately RMB 10,383,885,000 in 2019), an increase of 9.
3% over the previous year.
, Ltd.
announced its 2020 results.
In 2020, Weigao Co.
, Ltd.
and its subsidiaries recorded revenue of approximately RMB 11,345,252,000 (approximately RMB 10,383,885,000 in 2019), an increase of 9.
3% over the previous year.
The net profit attributable to owners was approximately RMB 2,030,137,000 (2019: approximately RMB 1,849,936,000), an increase of 9.
7% from the previous year.
Excluding special items, the net profit attributable to owners of the company was approximately RMB 2,030,137,000 (approximately RMB 1,928,445,000 in 2019), an increase of 5.
3% from the previous year.
7% from the previous year.
Excluding special items, the net profit attributable to owners of the company was approximately RMB 2,030,137,000 (approximately RMB 1,928,445,000 in 2019), an increase of 5.
3% from the previous year.
At the same time, the gross profit margin of Weigao shares dropped from 62.
7% last year to 56.
9%, mainly due to the impact of product structure changes.
7% last year to 56.
9%, mainly due to the impact of product structure changes.
It is understood that Weigao shares are mainly engaged in the research and development, production and sales of medical device products, orthopedics products, interventional products, pharmaceutical packaging products, blood management products, and operating financing business.
In terms of management, Weigao shares are currently divided into six business segments: medical device products, orthopedics products, interventional products, pharmaceutical packaging products, blood management products and others.
Interventional products are produced by Airang.
Interventional products are produced by Airang.
Two major businesses or split
In addition to changes in senior staff, Weigao shares are also continuously promoting the split at the business level.
On September 15, 2020, Weigao Co.
, Ltd.
issued an announcement stating that it is considering the possibility of splitting its R&D, manufacturing, sales and distribution of radiology, angiology, cardiology , and oncology disposable medical device businesses for interventional surgery and trading in approved securities Independently listed.
, Ltd.
issued an announcement stating that it is considering the possibility of splitting its R&D, manufacturing, sales and distribution of radiology, angiology, cardiology , and oncology disposable medical device businesses for interventional surgery and trading in approved securities Independently listed.
Prior to this announcement, Reuters’ IFR reported that Shandong Weigao may consider spin-off of its subsidiary Argon Medical Devices for listing.
The preferred location for the IPO may be Hong Kong, which is expected to be valued at US$2 billion to US$3 billion at the time of listing.
The preferred location for the IPO may be Hong Kong, which is expected to be valued at US$2 billion to US$3 billion at the time of listing.
It is understood that Airang is mainly engaged in the production and sales of medical devices used in interventional radiology, vascular surgery, interventional cardiology and oncology.
On January 23, 2018, Weigao’s 89.
81%-owned subsidiary WW Holding had a share of 54.
5 100 million yuan completed the acquisition of 100% shares of Airang.
On January 23, 2018, Weigao’s 89.
81%-owned subsidiary WW Holding had a share of 54.
5 100 million yuan completed the acquisition of 100% shares of Airang.
In February this year, Weigao shares continued to issue announcements showing that on February 25, 2021, its proposal to spin off Weigao Orthopedics for listing has been approved by the Science and Technology Innovation Board Listing Committee.
It is understood that Weigao Orthopedics is mainly engaged in the manufacture and sale of implantable orthopedic medical devices, including spinal, trauma and joint products.
It also produces surgical instruments and tools for spinal, trauma and joint implant surgery.
It also produces surgical instruments and tools for spinal, trauma and joint implant surgery.
It is worth noting that at the same time that the Weigao Orthopedics will be split, the national orthopedics collection will also be coming soon.
The impact of the split is still unknown.
The impact of the split is still unknown.
It is understood that on March 26, the Henan Provincial Medical Insurance Bureau issued a notice to launch the ten provinces (autonomous regions and municipalities) Orthopedic Trauma Medical Consumables Alliance to pharmnet.
com.
cn/news/yyzb/" target="_blank">purchase relevant production enterprise product information filling work, the alliance scope includes Henan Province, Shanxi Province, Jiangxi Province, Hubei Province, Chongqing City, Guizhou Province, Yunnan Province, Guangxi Zhuang Autonomous Region, Ningxia Hui Autonomous Region, Qinghai Province.
com.
cn/news/yyzb/" target="_blank">purchase relevant production enterprise product information filling work, the alliance scope includes Henan Province, Shanxi Province, Jiangxi Province, Hubei Province, Chongqing City, Guizhou Province, Yunnan Province, Guangxi Zhuang Autonomous Region, Ningxia Hui Autonomous Region, Qinghai Province.
On March 24, according to the Xiaoxiang Morning News, the Huanggang Medical Security Bureau organized public medical institutions in the city to collect data on orthopedic consumables in accordance with the requirements of the National Medical Insurance Bureau, marking the official start of the second batch of high-value orthopedic consumables.
Curtain, the centralized procurement products include artificial joints, spine, trauma and orthopedics high-value medical consumables.
Curtain, the centralized procurement products include artificial joints, spine, trauma and orthopedics high-value medical consumables.
Medical News, April 1st, Zhang Huawei resigned, Long Jing has been appointed
Chairman's resignation has taken effect
On March 30, Weigao Co.
, Ltd.
issued an announcement on "The appointment and resignation of directors, and the re-election of retiring independent non-executive directors and the chairman of the board of directors, chief executive officer and authorized representative changes for more than nine years.
, Ltd.
issued an announcement on "The appointment and resignation of directors, and the re-election of retiring independent non-executive directors and the chairman of the board of directors, chief executive officer and authorized representative changes for more than nine years.
The above announcement shows that Zhang Huawei has resigned as executive director, chairman of the board of directors and authorized representative of Weigao Co.
, Ltd.
, effective from March 30, 2021.
, Ltd.
, effective from March 30, 2021.
Wang Yi has resigned as an executive director of Weigao Co.
, Ltd.
, effective March 30, 2021.
, Ltd.
, effective March 30, 2021.
Long Jing has resigned as the chief executive officer of Weigao Co.
, Ltd.
, effective March 30, 2021.
Long Jing has been appointed as the chairman and authorized representative of Weigao, effective March 30, 2021.
, Ltd.
, effective March 30, 2021.
Long Jing has been appointed as the chairman and authorized representative of Weigao, effective March 30, 2021.
Cong Rinan has been appointed as the chief executive officer of Weigao Co.
, Ltd.
, effective from March 30, 2021.
He has been nominated as an executive director of Weigao shares, subject to shareholder approval, etc.
, Ltd.
, effective from March 30, 2021.
He has been nominated as an executive director of Weigao shares, subject to shareholder approval, etc.
According to the above announcement, Zhang Huawei has resigned as executive director, chairman of the board of directors and authorized representative of Ben Weigao Co.
, Ltd.
due to work arrangements.
He has confirmed that he has no disagreement with the board of directors, and there is no matter related to his resignation that needs to be brought to the Stock Exchange and shareholders.
Note.
, Ltd.
due to work arrangements.
He has confirmed that he has no disagreement with the board of directors, and there is no matter related to his resignation that needs to be brought to the Stock Exchange and shareholders.
Note.
Long Jing has resigned as the chief executive officer and has been appointed as the chairman and authorized representative of Weigao Co.
, Ltd.
, effective March 30, 2021.
In view of Weigao's leading position in the Chinese market, as well as the potential to expand into the global market with its extensive product portfolio and new products under development, this move aims to allow Longjing to focus on the Group's strategic planning and development.
Mr.
Long will continue to oversee business operations and the new CEO will report directly to him.
, Ltd.
, effective March 30, 2021.
In view of Weigao's leading position in the Chinese market, as well as the potential to expand into the global market with its extensive product portfolio and new products under development, this move aims to allow Longjing to focus on the Group's strategic planning and development.
Mr.
Long will continue to oversee business operations and the new CEO will report directly to him.
Annual results announcement
According to information on the official website of Weigao shares, Zhang Huawei is 56 years old and has served as the chairman and executive director of Weigao shares and chairman of Weigao Group Co.
, Ltd.
, Ltd.
Zhang Huawei studied politics and economics at Shandong University at Weihai from 1996 to 1998.
Zhang Huawei served as the deputy factory director of Weigao Group from 1988 to 1998 and the general manager of Weigao Group since 1998.
Zhang Huawei joined Weigao in December 2000.
Zhang Huawei served as the deputy factory director of Weigao Group from 1988 to 1998 and the general manager of Weigao Group since 1998.
Zhang Huawei joined Weigao in December 2000.
Long Jing is 45 years old and used to be the chief executive officer and executive director of Weigao Co.
, Ltd.
, responsible for the company's marketing management.
Longjing has more than ten years of valuable experience in sales and marketing in the Chinese medical device industry.
, Ltd.
, responsible for the company's marketing management.
Longjing has more than ten years of valuable experience in sales and marketing in the Chinese medical device industry.
Longjing joined Weigao Co.
, Ltd.
in July 2005 and served as the deputy manager and sales manager of the company's sales management department.
Before joining Weigao, Longjing served as a sales executive in Shandong Plastics Industry Corporation from 1996 to 2002, mainly responsible for the sales and marketing of raw materials.
, Ltd.
in July 2005 and served as the deputy manager and sales manager of the company's sales management department.
Before joining Weigao, Longjing served as a sales executive in Shandong Plastics Industry Corporation from 1996 to 2002, mainly responsible for the sales and marketing of raw materials.
On March 30, Weigao Co.
, Ltd.
announced its 2020 results.
In 2020, Weigao Co.
, Ltd.
and its subsidiaries recorded revenue of approximately RMB 11,345,252,000 (approximately RMB 10,383,885,000 in 2019), an increase of 9.
3% over the previous year.
, Ltd.
announced its 2020 results.
In 2020, Weigao Co.
, Ltd.
and its subsidiaries recorded revenue of approximately RMB 11,345,252,000 (approximately RMB 10,383,885,000 in 2019), an increase of 9.
3% over the previous year.
The net profit attributable to owners was approximately RMB 2,030,137,000 (2019: approximately RMB 1,849,936,000), an increase of 9.
7% from the previous year.
Excluding special items, the net profit attributable to owners of the company was approximately RMB 2,030,137,000 (approximately RMB 1,928,445,000 in 2019), an increase of 5.
3% from the previous year.
7% from the previous year.
Excluding special items, the net profit attributable to owners of the company was approximately RMB 2,030,137,000 (approximately RMB 1,928,445,000 in 2019), an increase of 5.
3% from the previous year.
At the same time, the gross profit margin of Weigao shares dropped from 62.
7% last year to 56.
9%, mainly due to the impact of product structure changes.
7% last year to 56.
9%, mainly due to the impact of product structure changes.
It is understood that Weigao shares are mainly engaged in the research and development, production and sales of medical device products, orthopedics products, interventional products, pharmaceutical packaging products, blood management products, and operating financing business.
In terms of management, Weigao shares are currently divided into six business segments: medical device products, orthopedics products, interventional products, pharmaceutical packaging products, blood management products and others.
Interventional products are produced by Airang.
Interventional products are produced by Airang.
Two major businesses or split
In addition to changes in senior staff, Weigao shares are also continuously promoting the split at the business level.
On September 15, 2020, Weigao Co.
, Ltd.
issued an announcement stating that it is considering the possibility of splitting its R&D, manufacturing, sales and distribution of radiology, angiology, cardiology , and oncology disposable medical device businesses for interventional surgery and trading in approved securities Independently listed.
, Ltd.
issued an announcement stating that it is considering the possibility of splitting its R&D, manufacturing, sales and distribution of radiology, angiology, cardiology , and oncology disposable medical device businesses for interventional surgery and trading in approved securities Independently listed.
Prior to this announcement, Reuters’ IFR reported that Shandong Weigao may consider spin-off of its subsidiary Argon Medical Devices for listing.
The preferred location for the IPO may be Hong Kong, which is expected to be valued at US$2 billion to US$3 billion at the time of listing.
The preferred location for the IPO may be Hong Kong, which is expected to be valued at US$2 billion to US$3 billion at the time of listing.
It is understood that Airang is mainly engaged in the production and sales of medical devices used in interventional radiology, vascular surgery, interventional cardiology and oncology.
On January 23, 2018, Weigao’s 89.
81%-owned subsidiary WW Holding had a share of 54.
5 100 million yuan completed the acquisition of 100% shares of Airang.
On January 23, 2018, Weigao’s 89.
81%-owned subsidiary WW Holding had a share of 54.
5 100 million yuan completed the acquisition of 100% shares of Airang.
In February this year, Weigao shares continued to issue announcements showing that on February 25, 2021, its proposal to spin off Weigao Orthopedics for listing has been approved by the Science and Technology Innovation Board Listing Committee.
It is understood that Weigao Orthopedics is mainly engaged in the manufacture and sale of implantable orthopedic medical devices, including spinal, trauma and joint products.
It also produces surgical instruments and tools for spinal, trauma and joint implant surgery.
It also produces surgical instruments and tools for spinal, trauma and joint implant surgery.
It is worth noting that at the same time that the Weigao Orthopedics will be split, the national orthopedics collection will also be coming soon.
The impact of the split is still unknown.
The impact of the split is still unknown.
It is understood that on March 26, the Henan Provincial Medical Insurance Bureau issued a notice to launch the ten provinces (autonomous regions and municipalities) Orthopedic Trauma Medical Consumables Alliance to pharmnet.
com.
cn/news/yyzb/" target="_blank">purchase relevant production enterprise product information filling work, the alliance scope includes Henan Province, Shanxi Province, Jiangxi Province, Hubei Province, Chongqing City, Guizhou Province, Yunnan Province, Guangxi Zhuang Autonomous Region, Ningxia Hui Autonomous Region, Qinghai Province.
com.
cn/news/yyzb/" target="_blank">purchase relevant production enterprise product information filling work, the alliance scope includes Henan Province, Shanxi Province, Jiangxi Province, Hubei Province, Chongqing City, Guizhou Province, Yunnan Province, Guangxi Zhuang Autonomous Region, Ningxia Hui Autonomous Region, Qinghai Province.
On March 24, according to the Xiaoxiang Morning News, the Huanggang Medical Security Bureau organized public medical institutions in the city to collect data on orthopedic consumables in accordance with the requirements of the National Medical Insurance Bureau, marking the official start of the second batch of high-value orthopedic consumables.
Curtain, the centralized procurement products include artificial joints, spine, trauma and orthopedics high-value medical consumables.
Curtain, the centralized procurement products include artificial joints, spine, trauma and orthopedics high-value medical consumables.
Medical News, April 1st, Zhang Huawei resigned, Long Jing has been appointed
Chairman's resignation has taken effect
Chairman's resignation has taken effect On March 30, Weigao Co.
, Ltd.
issued an announcement on "The appointment and resignation of directors, and the re-election of retiring independent non-executive directors and the chairman of the board of directors, chief executive officer and authorized representative changes for more than nine years.
, Ltd.
issued an announcement on "The appointment and resignation of directors, and the re-election of retiring independent non-executive directors and the chairman of the board of directors, chief executive officer and authorized representative changes for more than nine years.
The above announcement shows that Zhang Huawei has resigned as executive director, chairman of the board of directors and authorized representative of Weigao Co.
, Ltd.
, effective from March 30, 2021.
, Ltd.
, effective from March 30, 2021.
Wang Yi has resigned as an executive director of Weigao Co.
, Ltd.
, effective March 30, 2021.
, Ltd.
, effective March 30, 2021.
Long Jing has resigned as the chief executive officer of Weigao Co.
, Ltd.
, effective March 30, 2021.
Long Jing has been appointed as the chairman and authorized representative of Weigao, effective March 30, 2021.
, Ltd.
, effective March 30, 2021.
Long Jing has been appointed as the chairman and authorized representative of Weigao, effective March 30, 2021.
Cong Rinan has been appointed as the chief executive officer of Weigao Co.
, Ltd.
, effective from March 30, 2021.
He has been nominated as an executive director of Weigao shares, subject to shareholder approval, etc.
, Ltd.
, effective from March 30, 2021.
He has been nominated as an executive director of Weigao shares, subject to shareholder approval, etc.
According to the above announcement, Zhang Huawei has resigned as executive director, chairman of the board of directors and authorized representative of Ben Weigao Co.
, Ltd.
due to work arrangements.
He has confirmed that he has no disagreement with the board of directors, and there is no matter related to his resignation that needs to be brought to the Stock Exchange and shareholders.
Note.
, Ltd.
due to work arrangements.
He has confirmed that he has no disagreement with the board of directors, and there is no matter related to his resignation that needs to be brought to the Stock Exchange and shareholders.
Note.
Long Jing has resigned as the chief executive officer and has been appointed as the chairman and authorized representative of Weigao Co.
, Ltd.
, effective March 30, 2021.
In view of Weigao's leading position in the Chinese market, as well as the potential to expand into the global market with its extensive product portfolio and new products under development, this move aims to allow Longjing to focus on the Group's strategic planning and development.
Mr.
Long will continue to oversee business operations and the new CEO will report directly to him.
, Ltd.
, effective March 30, 2021.
In view of Weigao's leading position in the Chinese market, as well as the potential to expand into the global market with its extensive product portfolio and new products under development, this move aims to allow Longjing to focus on the Group's strategic planning and development.
Mr.
Long will continue to oversee business operations and the new CEO will report directly to him.
Annual results announcement
Annual results announcement According to information on the official website of Weigao shares, Zhang Huawei is 56 years old and has served as the chairman and executive director of Weigao shares and chairman of Weigao Group Co.
, Ltd.
, Ltd.
Zhang Huawei studied politics and economics at Shandong University at Weihai from 1996 to 1998.
Zhang Huawei served as the deputy factory director of Weigao Group from 1988 to 1998 and the general manager of Weigao Group since 1998.
Zhang Huawei joined Weigao in December 2000.
Zhang Huawei served as the deputy factory director of Weigao Group from 1988 to 1998 and the general manager of Weigao Group since 1998.
Zhang Huawei joined Weigao in December 2000.
Long Jing is 45 years old and used to be the chief executive officer and executive director of Weigao Co.
, Ltd.
, responsible for the company's marketing management.
Longjing has more than ten years of valuable experience in sales and marketing in the Chinese medical device industry.
, Ltd.
, responsible for the company's marketing management.
Longjing has more than ten years of valuable experience in sales and marketing in the Chinese medical device industry.
Longjing joined Weigao Co.
, Ltd.
in July 2005 and served as the deputy manager and sales manager of the company's sales management department.
Before joining Weigao, Longjing served as a sales executive in Shandong Plastics Industry Corporation from 1996 to 2002, mainly responsible for the sales and marketing of raw materials.
, Ltd.
in July 2005 and served as the deputy manager and sales manager of the company's sales management department.
Before joining Weigao, Longjing served as a sales executive in Shandong Plastics Industry Corporation from 1996 to 2002, mainly responsible for the sales and marketing of raw materials.
On March 30, Weigao Co.
, Ltd.
announced its 2020 results.
In 2020, Weigao Co.
, Ltd.
and its subsidiaries recorded revenue of approximately RMB 11,345,252,000 (approximately RMB 10,383,885,000 in 2019), an increase of 9.
3% over the previous year.
, Ltd.
announced its 2020 results.
In 2020, Weigao Co.
, Ltd.
and its subsidiaries recorded revenue of approximately RMB 11,345,252,000 (approximately RMB 10,383,885,000 in 2019), an increase of 9.
3% over the previous year.
The net profit attributable to owners was approximately RMB 2,030,137,000 (2019: approximately RMB 1,849,936,000), an increase of 9.
7% from the previous year.
Excluding special items, the net profit attributable to owners of the company was approximately RMB 2,030,137,000 (approximately RMB 1,928,445,000 in 2019), an increase of 5.
3% from the previous year.
7% from the previous year.
Excluding special items, the net profit attributable to owners of the company was approximately RMB 2,030,137,000 (approximately RMB 1,928,445,000 in 2019), an increase of 5.
3% from the previous year.
At the same time, the gross profit margin of Weigao shares dropped from 62.
7% last year to 56.
9%, mainly due to the impact of product structure changes.
7% last year to 56.
9%, mainly due to the impact of product structure changes.
It is understood that Weigao shares are mainly engaged in the research and development, production and sales of medical device products, orthopedics products, interventional products, pharmaceutical packaging products, blood management products, and operating financing business.
Medicine, medicine, medicine In terms of management, Weigao shares are currently divided into six business segments: medical device products, orthopedics products, interventional products, pharmaceutical packaging products, blood management products and others.
Interventional products are produced by Airang.
Medical equipment medical equipment medical equipmentInterventional products are produced by Airang.
Two major businesses or split
Two major businesses or split In addition to changes in senior staff, Weigao shares are also continuously promoting the split at the business level.
On September 15, 2020, Weigao Co.
, Ltd.
issued an announcement stating that it is considering the possibility of splitting its R&D, manufacturing, sales and distribution of radiology, angiology, cardiology , and oncology disposable medical device businesses for interventional surgery and trading in approved securities Independently listed.
Heart, heart, heart, Ltd.
issued an announcement stating that it is considering the possibility of splitting its R&D, manufacturing, sales and distribution of radiology, angiology, cardiology , and oncology disposable medical device businesses for interventional surgery and trading in approved securities Independently listed.
Prior to this announcement, Reuters’ IFR reported that Shandong Weigao may consider spin-off of its subsidiary Argon Medical Devices for listing.
The preferred location for the IPO may be Hong Kong, which is expected to be valued at US$2 billion to US$3 billion at the time of listing.
The preferred location for the IPO may be Hong Kong, which is expected to be valued at US$2 billion to US$3 billion at the time of listing.
It is understood that Airang is mainly engaged in the production and sales of medical devices used in interventional radiology, vascular surgery, interventional cardiology and oncology.
On January 23, 2018, Weigao’s 89.
81%-owned subsidiary WW Holding had a share of 54.
5 100 million yuan completed the acquisition of 100% shares of Airang.
On January 23, 2018, Weigao’s 89.
81%-owned subsidiary WW Holding had a share of 54.
5 100 million yuan completed the acquisition of 100% shares of Airang.
In February this year, Weigao shares continued to issue announcements showing that on February 25, 2021, its proposal to spin off Weigao Orthopedics for listing has been approved by the Science and Technology Innovation Board Listing Committee.
It is understood that Weigao Orthopedics is mainly engaged in the manufacture and sale of implantable orthopedic medical devices, including spinal, trauma and joint products.
It also produces surgical instruments and tools for spinal, trauma and joint implant surgery.
It also produces surgical instruments and tools for spinal, trauma and joint implant surgery.
It is worth noting that at the same time that the Weigao Orthopedics will be split, the national orthopedics collection will also be coming soon.
The impact of the split is still unknown.
The impact of the split is still unknown.
It is understood that on March 26, the Henan Provincial Medical Insurance Bureau issued a notice to launch the ten provinces (autonomous regions and municipalities) Orthopedic Trauma Medical Consumables Alliance to pharmnet.
com.
cn/news/yyzb/" target="_blank">purchase relevant production enterprise product information filling work, the alliance scope includes Henan Province, Shanxi Province, Jiangxi Province, Hubei Province, Chongqing City, Guizhou Province, Yunnan Province, Guangxi Zhuang Autonomous Region, Ningxia Hui Autonomous Region, Qinghai Province.
pharmnet. com.
cn/news/yyzb/" target="_blank">purchase relevant production enterprise product information filling work, the alliance scope includes Henan Province, Shanxi Province, Jiangxi Province, Hubei Province, Chongqing City, Guizhou Province, Yunnan Province, Guangxi Zhuang Autonomous Region, Ningxia Hui Autonomous Region, Qinghai Province.
com.
cn/news/yyzb/" target="_blank">Procurementpharmnet.
com.
cn/news/yyzb/" target="_blank"> Procurement Procurement Enterprise Enterprise Enterprise
On March 24, according to the Xiaoxiang Morning News, the Huanggang Medical Security Bureau organized public medical institutions in the city to collect data on orthopedic consumables in accordance with the requirements of the National Medical Insurance Bureau, marking the official start of the second batch of high-value orthopedic consumables.
Curtain, the centralized procurement products include artificial joints, spine, trauma and orthopedics high-value medical consumables.
Curtain, the centralized procurement products include artificial joints, spine, trauma and orthopedics high-value medical consumables.
